Vor Biopharma (VOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference